How Global Collaboration Can Improve the Medical Countermeasure Life Cycle for Infectious Disease Outbreaks.

Jessica Swenson, Gary Disbrow, Robert A Johnson

The Journal of infectious diseases 2024 Jul 25

filter terms:

Infectious disease outbreaks have become increasingly common and require global partnership for adequate preparedness and response. During outbreaks, medical countermeasures (MCMs)-vaccines, therapeutics, and diagnostics-need to reach patients quickly. Recent outbreaks exemplify that products with regulatory approval can expand access and reach patients quicker than investigational products. Unfortunately, insufficient funding globally and differences in funders' prioritization puts gains and future efforts at risk. Of primary concern is (1) lack of a feasible regulatory path and clinical capability to achieve regulatory approval for new MCMs for many diseases; and (2) the need for partners with the mandate, funding, and capabilities to support long-term sustainment of manufacturing capability and stockpiling of licensed products. Without collaboration, the global community runs the risk of losing the capabilities built through years of investment and being underprepared to combat future threats. Synergies between funders are critical to create long-term sustainment of products to ensure access. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Citation

Jessica Swenson, Gary Disbrow, Robert A Johnson. How Global Collaboration Can Improve the Medical Countermeasure Life Cycle for Infectious Disease Outbreaks. The Journal of infectious diseases. 2024 Jul 25;230(1):e1-e3